Therefore, we believe that a more complete inhibition of the PI3K and TORC1/2 pathway will increase HRD more than mTOR inhibition alone, sensitizing triple negative breast cancers to DNA damaging cisplatin and immune checkpoint inhibitors. The gene discussed is MTOR; the disease is triple-negative breast carcinoma.